|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancers (CRCs) frequently harbor somatic mutations in the pathway members TGFBR2 and SMAD4, but to what extent mutations in SMAD2 or SMAD3 contribute to tumorigenesis is unclear.
|
23139211 |
2013 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Smad4 plays a pivotal role in the TGF-beta signaling pathway and has been identified as a tumor suppressor, being mutated or deleted in approximately 50% of pancreatic carcinomas and 15% of colorectal cancers.
|
11553622 |
2001 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SMAD4 expression was absent in 20 of 53 (38%) unselected colorectal carcinomas, and reduced in another 15 (28%) cases.
|
12077092 |
2002 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
DPC4 protein may regulate proliferation of colorectal carcinoma cells by inhibiting cell growth and inducing cell apoptosis.
|
15637742 |
2005 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SMAD4 as a prognostic marker in colorectal cancer.
|
15814640 |
2005 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
|
16144935 |
2005 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
|
20565773 |
2010 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SMAD4 is a polypeptide with tumor suppressor function being investigated as a prognostic biomarker in Union Internationale Contre le Cancer stages II and III in previous studies, but its role as a prognostic marker in stage IV colorectal cancer (CRC) is still undefined.
|
21609932 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SMAD4 is a gastrointestinal malignancy-specific tumor suppressor gene found mutated in one third of colorectal cancer specimens and half of pancreatic tumors.
|
24625091 |
2014 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Smad4 is regarded as a tumor suppressor in colon cancer, but its role in lymphangiogenesis in colorectal cancer is still unclear.
|
25680269 |
2015 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
DPC4 and MADR2/JV18-1 are recently demonstrated to be altered in pancreatic and colorectal cancers, respectively.
|
9288786 |
1997 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A transducer of TGF-beta signaling known as Mothers against decapentaplegic homologue 4 (Smad4) is a known tumor suppressor found on chromosome 18q21.1 and is typically inactivated by deletion or mutation in pancreatic and colorectal cancers.
|
18213629 |
2008 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Alterations in transforming growth factor-beta signaling, due to a decrease in Smad2 and especially Smad4 expression, has primarily been reported in pancreatic and colorectal cancers, although loss of the chromosomal region 18q21.1, containing the loci of Smad2 and Smad4, is among the most frequent molecular alterations in cervical cancer.
|
18425078 |
2008 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although SMAD4 mutations have been associated with late-stage or metastatic disease, our combined molecular and cytogenetic data best fit a model in which SMAD4 mutations occur before colorectal cancers become aneuploid/polyploid, but after the MSI(+) and MSI(-) pathways diverge.
|
11481457 |
2001 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although Smad4 is regarded as a signaling mediator of the TGFβ signaling pathway, its role as a major suppressor of colorectal cancer progression and the molecular events underlying this phenomenon remain elusive.
|
21245094 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among 734 patients with CRC, 90 (12%) had SMAD4 mutations according to hotspot testing.
|
28267766 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
An inverse correlation between the levels of miR‑20a and SMAD4 was observed in patients with CRC.
|
24737193 |
2014 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
BMP signalling can be lost not only at the level of SMAD4 but also at the level of BMP receptors (BMPRs), as has been described in colorectal cancer.
|
23969729 |
2013 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
BMP signalling inhibits Wnt signalling in CRC only when p53 and SMAD4 are unaffected.
|
25393365 |
2015 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
BMPR2 expression is impaired more frequently in MSI CRCs than MSS (85% vs 29%; P < .0001) and shows a mutually exclusive pattern of impaired expression compared with SMAD4.
|
18471510 |
2008 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Compared to the 152 non-hypermutated CONs from TCGA database, SMAD4 alteration was predominant in SRC/SRCC (p = 0.045) with aberrant loss of SMAD4 expression (13/17, 76.5%) compared to the SMAD4 alterations in CON (5/15, 33.3%) (p = 0.031).
|
31400926 |
2019 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Correction: Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.
|
28545046 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Even in combination with changes in SMAD-4, the observed frequency was not sufficient to account for all 18q21 deletions in colorectal cancers.
|
9820171 |
1998 |